Cardiothoracic & vascular anesthesia
The effects of sodium-glucose transporter 2 inhibition on cardiac surgery-associated acute kidney injury: An open-label randomized pilot study
Authors' conclusion
In this pilot study, perioperative SGLT2 inhibition was not associated with lower NGAL levels. We observed that SGLT2 inhibition reduced the incidence of acute kidney injury in this small study population.
Study context
- Population
- Adults undergoing elective cardiac surgery with CPBintention-to-treat analysis
- Participants
- 55 adults
- Comparison
- Empagliflozin vs standard-of-care
- Empagliflozinn = 25
- Controln = 30reference
- Primary endpoint
- Between-group difference of serum NGAL
- Follow-up
- Second postoperative day
Methodological detailsopen-label, phase IV, parallel-group, pilot, March 2022 to April 2023
- Open-label
- Phase IV
- Parallel-group
- Pilot
- March 2022 to April 2023
Primary result
As reported in the abstract
Serum NGAL
- No significant between-group differences in serum and urine NGAL or KIM-1
- Intention-to-treat analysis
Further findings
AKI incidence (KDIGO criteria) · First 7 days after surgery
absolute difference 46.7 % (−69.7 - −23.6) · P < 0.001
Serum HIF-1α after surgery
- Significant increase solely in the control group
Safety
(Euglycemic) ketoacidosis or hypoglycemic events
- No between-group differences
Original publication
The effects of sodium-glucose transporter 2 inhibition on cardiac surgery-associated acute kidney injury: An open-label randomized pilot study. J Clin Anesth. Published 27 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →